6.025
2.43%
-0.15
Precipio Inc stock is currently priced at $6.025, with a 24-hour trading volume of 9,309.
It has seen a -2.43% decreased in the last 24 hours and a -10.07% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $6.06 pivot point. If it approaches the $5.82 support level, significant changes may occur.
Previous Close:
$6.175
Open:
$6.214
24h Volume:
9,309
Market Cap:
$8.62M
Revenue:
$15.20M
Net Income/Loss:
$-5.85M
P/E Ratio:
-0.6549
EPS:
-9.2
Net Cash Flow:
$-3.69M
1W Performance:
-4.82%
1M Performance:
-10.07%
6M Performance:
-20.83%
1Y Performance:
+887.70%
Precipio Inc Stock (PRPO) Company Profile
Name
Precipio Inc
Sector
Industry
Phone
203 787 7888
Address
4 Science Park, 3rd Floor, New Haven, CT
Precipio Inc Stock (PRPO) Latest News
Precipio Announces Year end 2023 Shareholder Update Call
GlobeNewswire Inc.
Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoY
GlobeNewswire Inc.
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for Cancer
GlobeNewswire Inc.
Precipio’s Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarter
GlobeNewswire Inc.
Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
GlobeNewswire Inc.
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024
GlobeNewswire Inc.
Precipio Inc Stock (PRPO) Financials Data
Precipio Inc (PRPO) Revenue 2024
PRPO reported a revenue (TTM) of $15.20 million for the quarter ending December 31, 2023, a +61.46% rise year-over-year.
Precipio Inc (PRPO) Net Income 2024
PRPO net income (TTM) was -$5.85 million for the quarter ending December 31, 2023, a +52.04% increase year-over-year.
Precipio Inc (PRPO) Cash Flow 2024
PRPO recorded a free cash flow (TTM) of -$3.69 million for the quarter ending December 31, 2023, a +53.93% increase year-over-year.
Precipio Inc (PRPO) Earnings per Share 2024
PRPO earnings per share (TTM) was -$4.56 for the quarter ending December 31, 2023, a +56.98% growth year-over-year.
About Precipio Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Cap:
|
Volume (24h):